Skip to main content
main-content
Erschienen in: best practice onkologie 7-8/2022

26.06.2022 | Zervixkarzinom | CME-Topic

Update S3-Leitlinie Zervixkarzinom

Diagnostik, Therapie und Nachsorge

verfasst von: Dr. Frederik A. Stübs, Matthias W. Beckmann, Tanja Fehm

Erschienen in: best practice onkologie | Ausgabe 7-8/2022

zum CME-Kurs Einloggen, um Zugang zu erhalten

Zusammenfassung

Die medizinische Versorgung von Patienteninnen mit einem Zervixkarzinom unterliegt einem ständigen Fortschritt. Daher müssen in regelmäßiger Weise die S3-Leitlinien überarbeitet und erneuert werden. Die neuen Statements und Empfehlungen beruhen auf einer systematischen Literaturrecherche und wurden durch ca. 50 Fachgesellschaften unter Begleitung durch die Arbeitsgemeinschaft der Wissenschaftlichen Medizinischen Fachgesellschaften (AWMF) erarbeitet. Der neue Standard in der operativen Therapie des Zervixkarzinoms bis zum FIGO(Fédération Internationale de Gynécologie et d'Obstétrique) Stadium IB1 ist die offene radikale Hysterektomie. In der Radio(chemo)therapie wurden die Daten zur intensitätsmodulierten Radiotherapie und individualisierten Brachytherapie gestärkt. Patientinnen mit metastasiertem Zervixkarzinom profitieren in der ersten Linie von der Hinzunahme des Antikörpers Bevacizumab sowie ab der zweiten Linie vom Einsatz des Checkpointinhibitors Pembrolizumab bei PD-L1-positiven Karzinomen.
Literatur
3.
Zurück zum Zitat Ramirez PT et al (2018) Minimally invasive versus abdominal radical hysterectomy for cervical cancer. N Engl J Med 379(20):1895–1904 CrossRef Ramirez PT et al (2018) Minimally invasive versus abdominal radical hysterectomy for cervical cancer. N Engl J Med 379(20):1895–1904 CrossRef
4.
Zurück zum Zitat Lande J et al (2007) Sentinel lymph node detection in early stage uterine cervix carcinoma: a systematic review (Provisional abstract). Gynecol Oncol 106:604–613 CrossRef Lande J et al (2007) Sentinel lymph node detection in early stage uterine cervix carcinoma: a systematic review (Provisional abstract). Gynecol Oncol 106:604–613 CrossRef
5.
Zurück zum Zitat Altgassen C et al (2008) Multicenter validation study of the sentinel lymph node concept in cervical cancer: AGO Study Group. J Clin Oncol 26(18):2943–2951 CrossRef Altgassen C et al (2008) Multicenter validation study of the sentinel lymph node concept in cervical cancer: AGO Study Group. J Clin Oncol 26(18):2943–2951 CrossRef
6.
Zurück zum Zitat Denschlag D, Woll J, Schneider A (2011) Stellenwert des Sentinel-Lymphknoten-Konzepts bei uterinen Karzinomen. Frauenarzt 52(1):46–51 Denschlag D, Woll J, Schneider A (2011) Stellenwert des Sentinel-Lymphknoten-Konzepts bei uterinen Karzinomen. Frauenarzt 52(1):46–51
7.
Zurück zum Zitat Selman TJ et al (2008) Diagnostic accuracy of tests for lymph node status in primary cervical cancer: a systematic review and meta-analysis (Structured abstract). CMAJ (Ottawa) 178:855–862 CrossRef Selman TJ et al (2008) Diagnostic accuracy of tests for lymph node status in primary cervical cancer: a systematic review and meta-analysis (Structured abstract). CMAJ (Ottawa) 178:855–862 CrossRef
8.
Zurück zum Zitat Tax C et al (2015) The sentinel node procedure in early stage cervical cancer, taking the next step; a diagnostic review. Gynecol Oncol 139(3):559–567 CrossRef Tax C et al (2015) The sentinel node procedure in early stage cervical cancer, taking the next step; a diagnostic review. Gynecol Oncol 139(3):559–567 CrossRef
9.
Zurück zum Zitat Wang XJ, Fang F, Li YF (2015) Sentinel-lymph-node procedures in early stage cervical cancer: a systematic review and meta-analysis. Med Oncol 32(1):385 CrossRef Wang XJ, Fang F, Li YF (2015) Sentinel-lymph-node procedures in early stage cervical cancer: a systematic review and meta-analysis. Med Oncol 32(1):385 CrossRef
10.
Zurück zum Zitat Frumovitz M et al (2018) Near-infrared fluorescence for detection of sentinel lymph nodes in women with cervical and uterine cancers (FILM): a randomised, phase 3, multicentre, non-inferiority trial. Lancet Oncol 19(10):1394–1403 CrossRef Frumovitz M et al (2018) Near-infrared fluorescence for detection of sentinel lymph nodes in women with cervical and uterine cancers (FILM): a randomised, phase 3, multicentre, non-inferiority trial. Lancet Oncol 19(10):1394–1403 CrossRef
11.
Zurück zum Zitat Wang N et al (2011) Radiochemotherapy versus radiotherapy in locally advanced cervical cancer: a meta-analysis. Arch Gynecol Obstet 283(1):103–108 CrossRef Wang N et al (2011) Radiochemotherapy versus radiotherapy in locally advanced cervical cancer: a meta-analysis. Arch Gynecol Obstet 283(1):103–108 CrossRef
12.
Zurück zum Zitat Du XL et al (2012) Intensity-modulated radiation therapy for advanced cervical cancer: a comparison of dosimetric and clinical outcomes with conventional radiotherapy. Gynecol Oncol 125(1):151–157 CrossRef Du XL et al (2012) Intensity-modulated radiation therapy for advanced cervical cancer: a comparison of dosimetric and clinical outcomes with conventional radiotherapy. Gynecol Oncol 125(1):151–157 CrossRef
13.
Zurück zum Zitat Gandhi AK et al (2013) Early clinical outcomes and toxicity of intensity modulated versus conventional pelvic radiation therapy for locally advanced cervix carcinoma: a prospective randomized study. Int J Radiat Oncol Biol Phys 87(3):542–548 CrossRef Gandhi AK et al (2013) Early clinical outcomes and toxicity of intensity modulated versus conventional pelvic radiation therapy for locally advanced cervix carcinoma: a prospective randomized study. Int J Radiat Oncol Biol Phys 87(3):542–548 CrossRef
14.
Zurück zum Zitat Marnitz S et al (2015) Which technique for radiation is most beneficial for patients with locally advanced cervical cancer? Intensity modulated proton therapy versus intensity modulated photon treatment, helical tomotherapy and volumetric arc therapy for primary radiation—an intraindividual comparison. Radiat Oncol 10. https://​doi.​org/​10.​1186/​s13014-015-0402-z Marnitz S et al (2015) Which technique for radiation is most beneficial for patients with locally advanced cervical cancer? Intensity modulated proton therapy versus intensity modulated photon treatment, helical tomotherapy and volumetric arc therapy for primary radiation—an intraindividual comparison. Radiat Oncol 10. https://​doi.​org/​10.​1186/​s13014-015-0402-z
15.
Zurück zum Zitat Lin Y et al (2018) Intensity-modulated radiation therapy for definitive treatment of cervical cancer: a meta-analysis. Radiat Oncol 13(1):177 CrossRef Lin Y et al (2018) Intensity-modulated radiation therapy for definitive treatment of cervical cancer: a meta-analysis. Radiat Oncol 13(1):177 CrossRef
16.
Zurück zum Zitat Peng YH et al (2016) Neo-adjuvant chemotherapy plus surgery versus surgery alone for cervical cancer: meta-analysis of randomized controlled trials. J Obstet Gynaecol Res 42(2):128–135 CrossRef Peng YH et al (2016) Neo-adjuvant chemotherapy plus surgery versus surgery alone for cervical cancer: meta-analysis of randomized controlled trials. J Obstet Gynaecol Res 42(2):128–135 CrossRef
17.
Zurück zum Zitat Gouy S et al (2013) Prospective multicenter study evaluating the survival of patients with locally advanced cervical cancer undergoing laparoscopic para-aortic lymphadenectomy before chemoradiotherapy in the era of positron emission tomography imaging. J Clin Oncol 31(24):3026–3033 CrossRef Gouy S et al (2013) Prospective multicenter study evaluating the survival of patients with locally advanced cervical cancer undergoing laparoscopic para-aortic lymphadenectomy before chemoradiotherapy in the era of positron emission tomography imaging. J Clin Oncol 31(24):3026–3033 CrossRef
18.
Zurück zum Zitat De Cuypere M et al (2020) Added value of para-aortic surgical staging compared to (18)F-FDG PET/CT on the external beam radiation field for patients with locally advanced cervical cancer: An ONCO-GF study. Eur J Surg Oncol 46(5):883–887 CrossRef De Cuypere M et al (2020) Added value of para-aortic surgical staging compared to (18)F-FDG PET/CT on the external beam radiation field for patients with locally advanced cervical cancer: An ONCO-GF study. Eur J Surg Oncol 46(5):883–887 CrossRef
19.
Zurück zum Zitat Martinez A et al (2020) Tumour and pelvic lymph node metabolic activity on FDG-PET/CT to stratify patients for para-aortic surgical staging in locally advanced cervical cancer. Eur J Nucl Med Mol Imaging 47(5):1252–1260 CrossRef Martinez A et al (2020) Tumour and pelvic lymph node metabolic activity on FDG-PET/CT to stratify patients for para-aortic surgical staging in locally advanced cervical cancer. Eur J Nucl Med Mol Imaging 47(5):1252–1260 CrossRef
22.
Zurück zum Zitat Frenel JS et al (2017) Safety and efficacy of pembrolizumab in advanced, programmed death ligand 1-positive cervical cancer: results from the phase Ib KEYNOTE-028 trial. J Clin Oncol 35(36):4035–4041 CrossRef Frenel JS et al (2017) Safety and efficacy of pembrolizumab in advanced, programmed death ligand 1-positive cervical cancer: results from the phase Ib KEYNOTE-028 trial. J Clin Oncol 35(36):4035–4041 CrossRef
23.
Zurück zum Zitat Chung HC et al (2019) Efficacy and safety of pembrolizumab in previously treated advanced cervical cancer: results from the phase II KEYNOTE-158 study. J Clin Oncol 37(17):1470–1478 CrossRef Chung HC et al (2019) Efficacy and safety of pembrolizumab in previously treated advanced cervical cancer: results from the phase II KEYNOTE-158 study. J Clin Oncol 37(17):1470–1478 CrossRef
25.
Zurück zum Zitat Tewari KS et al (2021) ESMO 2021, Special Session—Virtual Plenary Debate. Abstract No. VP4 Tewari KS et al (2021) ESMO 2021, Special Session—Virtual Plenary Debate. Abstract No. VP4
26.
Zurück zum Zitat Coleman RL et al (2021) Efficacy and safety of tisotumab vedotin in previously treated recurrent or metastatic cervical cancer (innovaTV 204/GOG-3023/ENGOT-cx6): a multicentre, open-label, single-arm, phase 2 study. Lancet Oncol 22(5):609–619 CrossRef Coleman RL et al (2021) Efficacy and safety of tisotumab vedotin in previously treated recurrent or metastatic cervical cancer (innovaTV 204/GOG-3023/ENGOT-cx6): a multicentre, open-label, single-arm, phase 2 study. Lancet Oncol 22(5):609–619 CrossRef
Metadaten
Titel
Update S3-Leitlinie Zervixkarzinom
Diagnostik, Therapie und Nachsorge
verfasst von
Dr. Frederik A. Stübs
Matthias W. Beckmann
Tanja Fehm
Publikationsdatum
26.06.2022
Verlag
Springer Medizin
Erschienen in
best practice onkologie / Ausgabe 7-8/2022
Print ISSN: 0946-4565
Elektronische ISSN: 1862-8559
DOI
https://doi.org/10.1007/s11654-022-00405-4